Relay Therapeutics, Inc.·4

Apr 30, 4:22 PM ET

Catinazzo Thomas 4

Research Summary

AI-generated summary

Updated

Relay Therapeutics (RLAY) CFO Thomas Catinazzo Sells 972 Shares

What Happened

  • Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), disposed of 972 shares on April 28, 2026 at $14.79 per share, generating proceeds of $14,376. The sale was reported as an open market/private sale (code S).
  • According to the filing, the sale was executed solely to satisfy income tax withholding obligations arising from the vesting of 3,268 restricted stock units (RSUs) on April 27, 2026; the reporting person had no discretion over the sale and it followed the issuer’s RSU vesting policies.

Key Details

  • Transaction date & price: 2026-04-28, 972 shares @ $14.79 each — $14,376 total.
  • Reason/footnote: F1 — sale to cover tax withholding on RSU vesting (non‑discretionary).
  • Holdings note: F2 — filing indicates inclusion of 9,807 shares underlying RSUs in the reporting person’s holdings.
  • Filing date/timeliness: Form 4 filed 2026-04-30; this is within the standard 2-business‑day window and not late.
  • Transaction codes: S = Sale; related withholding/tax action noted in footnote F1.

Context

  • This was a routine, non-discretionary sale to cover tax withholding on vested RSUs rather than a discretionary stock sale for investment reasons. Such withholding sales are common and generally not interpreted as a direct signal of management’s view on the company’s stock.